Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
157
resultados
Última actualización
16/10/2026 [07:44:00]
Resultados 75 a 100 de 157
Resumen de: WO2026189517A1
Disclosure herein Mirtazapine for use in treating bulbar-onset ALS (amyotrophic lateral sclerosis), and kit comprising Mirtazapine for treating bulbar-onset ALS. Also disclosed herein a method for treating bulbar-onset ALS comprising administration of Mirtazapine, optionally with an additional therapy for treating ALS.
Resumen de: AU2026226429A1
An effective amount of quercetin, vitamin B3, vitamin C, zafirlukast and optionally folic acid for use in treating amyotrophic lateral sclerosis in a subject. Also disclosed are said combination for use in reducing, slowing or abating the progression of amyotrophic lateral sclerosis or a symptom thereof. ep e p
Resumen de: US20260272976A1
Described herein are methods of monitoring and treating a subject with ALS based on biomarkers.
Resumen de: WO2026189377A1
Provided is use of an RIPK1 inhibitor in the treatment of Alzheimer's disease. Specifically, provided is a potential treatment method for Alzheimer's disease. The method uses the RIPK1 inhibitor to ameliorate and inhibit brain inflammation and the development of Alzheimer's disease caused by changes in the activity or expression level of myeloid INPP5D or RIPK1 activation, thereby ameliorating symptoms of late-onset Alzheimer's disease, especially early AD progression, and reducing brain inflammation associated with Alzheimer's disease.
Resumen de: US20260275351A1
Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a Superoxide Dismutase 1 (SOD1) gene. The SOD1 RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an SOD1 gene. Pharmaceutical compositions that include one or more SOD1 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described SOD1 RNAi agents to central nervous system (CNS) tissue, in vivo, provides for inhibition of SOD1 gene expression and a reduction in SOD1 activity, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including amyotrophic lateral sclerosis (ALS).
Resumen de: AU2025215085A1
Disclosed herein is a compound of Formulas (I) and (II) as an FTO inhibitor with novel structures. Also disclosed herein is a pharmaceutical composition comprising the same, and a method of inhibiting weight gain, promoting weight loss, reducing serum LDL, cholesterol, LDL-c, or triglycerides, or treating obesity or an obesity-related disease (esp. obesity-related diabetes, hyperglycemia, diabetic nephropathy, hyperlipemia, coronary heart disease, atherosclerosis, hypertension, cardiovascular or cerebrovascular disease) or Alzheimer's disease by inhibiting FTO by using the compound disclosed herein.
Resumen de: WO2026193437A1
The present disclosure provides methods and kits related to treatment of Parkinson's disease in a subject by reducing the expression of a CaV1.3 protein in a target cell by administering to the subject a therapeutically effective amount of an engineered genetic system.
Resumen de: AU2025225323A1
The present invention relates to a solid composition, and its use in the treatment of Parkinson's disease, comprising at least two compartments, a first active pharmaceutical ingredient (API) and a second API, preferably for increasing uptake of the second API thereby optimizing its use in the treatment of Parkinson's disease, in particular improving its clinical activity and reducing its side effects associated with the treatment of Parkinson's disease.
Resumen de: EP4806513A2
Die vorliegende Erfindung Erfindung betrifft Derivate der Malonsäure zur Verwendung als Arzneimittel zur Behandlung einer neurodegenerativen Erkrankung bei einem Patienten, dadurch gekennzeichnet, dassa) das Malonsäure-Derivat der nachstehenden Formel (I) entspricht:worin X und Y jeweils unabhängig aus -O-M+, -OR1 und -NR2R3 ausgewählt sind, worin M+ aus ein- oder mehrwertigen Metallkationen ausgewählt ist und R1, R2 und R3 jeweils unabhängig aus Wasserstoff und gesättigten oder ungesättigten, unverzweigten, verzweigten oder zyklischen Kohlenwasserstoff-Resten mit 1 bis 15 Kohlenstoffatomen ausgewählt sind, worin ein oder mehrere Kohlenstoffatome gegebenenfalls durch O oder N ersetzt sind, wobei R2 und R3 gegebenenfalls miteinander verbunden sind und zusammen mit dem Stickstoffatom einen heterozyklischen Kohlenwasserstoff-Rest bilden; mit der Maßgabe, dass R2 und R3 keine Phenylreste sind; undb) die Behandlung der neurodegenerativen Erkrankung mittels Förderung der Metallothionein-Biosynthese zur Wiederherstellung der Metallhomöostase des Patienten erfolgt;und mit der Maßgabe, dass das Malonsäure-Derivat der Formel (I) keines der folgenden ist: Malonsäure, Malonsäurediamid, Dinatriummalonat, Malonsäuredimethylester, Malonsäuremethylester-Kaliumsalz, Malonsäuremethylesteramid, N-(3-Aminopropyl)-malonsäureamid, Malons
Resumen de: WO2025101652A1
Described herein are compounds that are MST1 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MST1 activity, such as diabetes and liver regeneration.
Resumen de: KR20260136354A
본 발명은 바닐릭산 유도체 화합물에 관한 것으로서, 바닐릭산과 카테콜아민 간의 탈수축합반응에 의해 형성될 수 있다. 본 발명에 따른 바닐릭산 유도체 화합물은 알츠하이머병 및 신경염증 치료제제로 사용할 수 있다는 점에 특징이 있다. 또한 본 발명은 상기 화합물을 포함하는 알츠하이머 치료제 조성물 및 신경염증 치료제 조성물에 관한 것이다.
Resumen de: KR20260135747A
본 발명은 HCN1 채널의 CNBD 도메인에 특이적으로 결합하는 세계 최초의 소분자 개방제(ind_5F_3pyr, 5-플루오로-1H-인다졸-3-일-피리딘-3-일)에 관한 것이다. 알츠하이머병에서 HCN1 채널 발현이 감소하여 신경 흥분성 이상이 발생하며, 기존 HCN 약물은 모두 차단제로서 이를 해결할 수 없다. 본 발명의 화합물은 HCN1 CNBD에 cAMP보다 강하게 결합하고(ΔG = -8.08 vs -7.51 kcal/mol), 열린 상태를 안정화하며(apo ΔG = -8.32), 혈액뇌장벽을 투과하고(MW 213, TPSA 57), TRIP8b 대체를 통한 뇌 선택성을 달성한다. 119개 후보 중 가상 스크리닝과 분자동역학으로 동정되었다. JPEGpat00001.jpg5157
Resumen de: WO2026188235A1
The present disclosure relates to methods of preventing and/or treating neuroinflammation in a subject in need thereof. The present disclosure also relates to methods and systems for modeling aging related neurodegenerative diseases (e.g., Amyotrophic lateral sclerosis (ALS)) in vitro. The methods comprise administering one or more Angiotensin II Receptor I Blocker (ARB) to the subject. The present disclosure also relates to methods and systems for modeling aging related neurodegenerative diseases (e.g., ALS) in vitro.
Resumen de: WO2026188223A1
The compositions and methods described herein include methods and agents that inhibit inflammasome signaling in a mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s) or other agents. Also described herein are compositions and methods of use thereof for detecting and treating early-stage Alzheimer's disease as well as other inflammatory neurologic conditions such as Huntington's Disease.
Resumen de: WO2026187186A1
The present invention relates to a vanillic acid derivative compound that can be formed by a dehydration condensation reaction between vanillic acid and catecholamine. The vanillic acid derivative compound according to the present invention can be used as a therapeutic agent for Alzheimer's disease and neuroinflammation. In addition, the present invention relates to a therapeutic agent composition for Alzheimer's disease and a therapeutic agent composition for neuroinflammation, each comprising the compound.
Resumen de: WO2026187862A1
Disclosed herein are compounds of the formula: (I), as well as pharmaceutical compositions thereof, wherein the variables are defined herein. In some aspects, the compounds and compositions provided herein may be used to treat neurodegenerative disorders, such as Alzheimer's disease. Also provided are methods of administering compounds and compositions provided herein to a patient in need thereof.
Resumen de: WO2026187868A1
The present disclosure provides specific anti-ac-tauK174, anti-ac-tauK274, and ac-tauK353 antibodies, or antigen-binding fragments thereof, and methods of their use in diagnosing, differentiating, targeting, staging, prognosing, and/or treating Alzheimer's Disease and related tauopathies, including traumatic brain injury. Methods of identifying a subject having early Alzheimer's Disease and related tauopathies are also provided, the methods comprising detecting proteins using at least one anti-ac-tauK174 antibody, at least one anti-ac-tauK274 antibody, and/or at least one anti-ac-tauK353 antibody. In some embodiments, the subject is ApoE4-positive.
Resumen de: US20260263349A1
A delayed timed release pharmaceutical composition, a preparation method therefor, and use thereof. The pharmaceutical composition comprises a tablet core. The tablet core comprises a drug-containing layer and a boosting layer stacked on the drug-containing layer. The drug-containing layer comprises a drug active ingredient. The drug active ingredient is levodopa or a derivative thereof, or a mixture of levodopa or a derivative thereof and a DOPA decarboxylase inhibitor, and accounts for 5-72.5 wt % of the content of the drug-containing layer. The pharmaceutical composition is a capsule-shaped tablet, can realize the effects of 1-3 h delayed release of the drug active ingredient and reaching a peak concentration at 6-10 h, can be used for reducing morning stiffness in patients with Parkinson's disease, and has good application prospects.
Resumen de: US20260263525A1
A cell culture protocol for obtaining neural progenitor cells from induced pluripotent stem cells is described. Also described are a pharmaceutical composition and a medicament containing the neural progenitor stem cells for use in the treatment of neuro degenerative disorders such as Parkinson's disease as described.
Resumen de: WO2026185857A1
A method for preventing and/or treating a disease or disorder selected from the group consisting of neurodegenerative disease, hepatic or renal disease, pulmonary disease, cardiovascular disease, cerebrovascular disease, metabolic disease, diabetes mellitus, substance use disorder (SUD), solid tumor, and any combination thereof, by administering a therapeutically effective amount of at least one anti-protozoal compound, e.g., anti-malarial and/or anti-toxoplasma compound, potentially targeting Plasmodium and/or Toxoplasma gondii. The composition may include atovaquone, proguanil, or a combination thereof with possible adjunctive therapies. Further provided are methods and kits for diagnosing Alzheimer's disease or determining an increased risk of developing Alzheimer's disease in a subject.
Resumen de: WO2026185478A1
The present invention relates to compounds of formula (I) that can be employed in the treatment, alleviation or prevention of a group of diseases, disorders and or abnormality associated with Tau protein aggregates, including, but not limited to, Alzheimer's disease (AD). The present invention also relates to, pharmaceutical compositions comprising said compounds, methods using said compounds, combinations comprising said compounds, medicaments containing them, and their uses in diseases, disorders and/or abnormalities associated with Tau protein aggregates.
Resumen de: US20260263386A1
The present invention pertains to the anti-inflammatory therapeutic effect of xantohumol in spinal cord injury (SCI). The continuous administration of xanthohumol for 1-8 weeks to SCI rats resulted in improved results in 4 clinical tests used and in lowering and faster elimination of macrophages from the SCI lesion. Since the infiltration of the SCI lesion by numerous phagocytic macrophages indicates a severe destructive inflammation of extraordinary longevity, administration of xanthohumol is neuroprotective and resulted in a better and faster recovery of the locomotor function and the strength and sensory function in the hind limbs, in a shorter period of paralysis of the urinary bladder and in the recovery of the body weight lost due to the SCI surgery. Since the traumatic brain injury (TBI) involving the white matter, and stroke involving the white matter initiate the severe destructive inflammation as in the SCI, the administration of xanthohumol is expected to be anti-inflammatory and neuroprotective in both brain diseases. Since neurodegenerative diseases including Alzheimer's disease, frontotemporal dementia and Parkinson's disease, immune mediated neuroinflammation including multiple sclerosis and neuromyelitis optica and cerebrospinal infections have inflammatory pathogenesis involving microgliosis and infiltration by macrophages, the administration of xanthohumol is expected to result in therapeutic inhibition of progression of all above diseases as well as of rela
Resumen de: US20260265261A1
Compounds of Formula I:and pharmaceutically acceptable salts thereof are provided for as inhibitors of SGK-1 for example for the treatment of conditions such as Long QT syndrome, heart failure, arrhythmia, ischemic injury, ischemic infarction, cardiac fibrosis, vascular proliferation, restenosis, dilated cardiomyopathy, stent failure, prostate cancer, epilepsy, colorectal cancer, breast cancer, Parkinson's disease and Lafora disease.
Resumen de: AU2025234423A1
Provided are compositions for delivery of zinc finger fusion proteins that inhibit expression of tau in the nervous system using the blood-brain barrier penetrant AAV capsid proteins comprising SEQ ID. NO: 1235, and methods of using the compositions to treat neurodegenerative diseases such as Alzheimer's disease, frontotemporal dementia, and other tauopathies.
Nº publicación: AU2025232421A1 10/09/2026
Solicitante:
PRAXIS PRECISION MEDICINES INC
PRAXIS PRECISION MEDICINES, INC.
Resumen de: AU2025232421A1
Described herein, in part, are methods useful for preventing and/or treating a disease or condition relating to aberrant function or activity of a T-type calcium channel, such as Parkinson's disease, psychiatric disorders (e.g., mood disorder (e.g., major depressive disorder)), pain, tremor (e.g., essential tremor), seizures (e.g., absence seizures), epilepsy, or an epilepsy syndrome (e.g., juvenile myoclonic epilepsy). The present invention further comprises methods for modulating the function of a T-type calcium channel and methods of administering a titrated dosage of a T-type calcium channel antagonist.
BOPI
Sede Electrónica
